Recent Analysts’ Ratings Changes for Prothena (PRTA)

A number of firms have modified their ratings and price targets on shares of Prothena (NASDAQ: PRTA) recently:

• 7/25/2026 – Prothena was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/24/2026 – Prothena had its “buy” rating reaffirmed by UBS Group AG.
• 7/24/2026 – Prothena had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.
• 7/9/2026 – Prothena was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/23/2026 – Prothena was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/6/2026 – Prothena was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/2/2026 – Prothena was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Buying and Selling at Prothena

In other Prothena news, major shareholder William P. Scully purchased 20,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $7.90 per share, for a total transaction of $158,000.00. Following the completion of the purchase, the insider directly owned 756,000 shares in the company, valued at approximately $5,972,400. This represents a 2.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased 345,000 shares of company stock worth $3,097,250 in the last 90 days. 10.40% of the stock is currently owned by corporate insiders.

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.